• Heidelberg Pharma presented new Phase I/IIa data on pamlectabart tismanitin at the IMS Annual Meeting 2026.
• The trial supported a Phase 2 dose selection, with safety remaining favorable and no dose-limiting ceiling identified.
• Responses were reported in heavily pretreated relapsed or refractory multiple myeloma patients, supporting further development.
• A Phase IIa expansion in relapsed or refractory multiple myeloma is ongoing, with enrollment progressing as planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heidelberg Pharma AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2404716_en) on September 24, 2026, and is solely responsible for the information contained therein.